OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cystic Fibrosis is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	233
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	117
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	87
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	80
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	79
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	78
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	74
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	73
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	68
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	67
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	63
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	63
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	62
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	62
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	56
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	56
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	55
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	53
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	46
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	45
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	45
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	45
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	44
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	44
463: Clearance of colonized bacterial species in CF patients before and after elexacaftor/tezacaftor/ivacaftor	43

410 Multidisciplinary collaboration for transition readiness and planning	42
460: Prevalence of antimicrobial resistance mutations in Mycobacterium abscessus and associations with in vitro susceptibility testing	41
465: Intestinal function and transit relates to microbial dysbiosis in the CF gut	40
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	38
568: Quantifying regional pulmonary ventilation changes pre-/postivacaftor treatment in same subject using hyperpolarized 3He MRI	38
585: Development of a novel, cell-free, in vitro, high-throughput screening system for readthrough agents of nonsense mutations	36
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	35
620: Iterative screen identifies amphiphilic peptides that confer enhanced delivery of CRISPR-associated nucleases and adenine base editors to airway epithelia	35
488: Bile acids, bacterial colonization, and lung inflammatory markers in infants with cystic fibrosis	34
P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	34
508: Extracellular vesicles mediate bacteria–immune cell interactions in the respiratory tract	34
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	34
462 Cystic fibrosis mental health and wellness questionnaire—factors and properties	34